PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
2.58%
ROE exceeding 1.5x Medical - Pharmaceuticals median of 0.60%. Joel Greenblatt would check if high returns reflect a sustainable advantage.
1.29%
Positive ROA while Medical - Pharmaceuticals median is negative. Philip Fisher would see if the firm has a stronger model than peers.
3.20%
ROCE exceeding 1.5x Medical - Pharmaceuticals median of 0.60%. Joel Greenblatt would look for a high return on incremental capital.
21.10%
Gross margin 50-75% of Medical - Pharmaceuticals median of 41.02%. Guy Spier would question if commodity-like dynamics exist.
3.59%
Margin of 3.59% while Medical - Pharmaceuticals median is zero. Walter Schloss would see if moderate profitability can be leveraged further.
2.57%
Net margin of 2.57% while Medical - Pharmaceuticals is zero. Walter Schloss would examine if modest profitability can expand.